Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics Inc (NQ: ALLO )

7.780 -0.430 (-5.24%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,076,598
Open 8.000
Bid (Size) 7.500 (26)
Ask (Size) 7.780 (9)
Prev. Close 8.210
Today's Range 7.665 - 8.110
52wk Range 5.405 - 17.49
Shares Outstanding 142,183,418
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
From Allogene Therapeutics, Inc.
Via Globe NewsWire

Performance

YTD
+35.07%
+35.07%
1 Month
+33.91%
+33.91%
3 Month
-14.22%
-14.22%
6 Month
-51.25%
-51.25%
1 Year
-29.40%
-29.40%

More News

Read More
Why Allogene Therapeutics Shares Are Seeing Blue Skies Today
Via Benzinga
Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma
From Allogene Therapeutics, Inc.
Via Globe NewsWire
5 Analysts Have This to Say About Allogene Therapeutics
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023
Via Benzinga
Amazon To Rally Over 28%? Here Are 10 Other Analyst Forecasts For Tuesday
Via Benzinga
Expert Ratings for Allogene Therapeutics
Via Benzinga
Yext, 1-800-Flowers.com And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
Via Benzinga
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via Globe NewsWire
WWE, AMTD Digital And Some Other Big Stocks Moving Higher In Friday's Pre-Market Session
Via Benzinga
Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?
Via Investor's Business Daily
Top 10 Highest Short Interest Stocks And 10 With Highest Cost To Borrow: Where Do Carvana, MicroStrategy, Fisker And AMC Rank?
Via Benzinga
RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
Via Benzinga
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
Via Benzinga
Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.